All In MedTech

Device Trial Radar · NCT02880514

In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia

A Clinical Evaluation of Propel Mini Sinus Implant Placement in the Frontal Sinus Ostia Following In-office Dilation

Last checked: Nov 20, 2026Latest source record: Dec 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Aug 2016

Primary completion

Dec 2016

Study completion Jun 2017

Sponsor

Lead sponsor
Intersect ENTNot on our public-company list
Sponsor type
Industry
First posted
Aug 26, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized controlled trial

Conditions

  • Chronic Sinusitis

Interventions

  • PROPEL Mini Sinus ImplantDevice

    Sinus implant with 370 mcg of mometasone furoate released over 30 days

  • Balloon Sinus Dilation AloneProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patency RateTime frame: Day 30

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Sacramento ENT

    Sacramento, California

  • ENT Assoicates of South Florida

    Boca Raton, Florida

  • ENT of Georgia

    Atlanta, Georgia

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.